KEYTRUDA-Pembrolizumab Immunotherapy for Solid Tumors: Mechanism of Action, Indication, Side Effects
KEYTRUDA a-k-a Pembrolizumab is a programmed death receptor-1 (PD 1)-blocking antibody Pembrolizumab is a humanized monoclonal IgG4 kappa antibody with an approximate molecular weight of 149 kDa. Pembrolizumab is produced in recombinant Chinese hamster ovary (CHO) cells. KEYTRUDA (Pembrolizumab) Indications KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma- for the treatment of patients with unresectable or metastatic melanoma Non-Small Cell Lung Cancer (NSCLC) Small Cell Lung Cancer (SCLC)- for the treatment of patients with metastatic SCLC with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy Head and Neck Squamous Cell Cancer (HNSCC) -in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC Classical Hodgkin Lymphoma (cHL)- for the treatment of adult patients with relapsed or refractory cHL & for the...